Examining and investigating the impact of demographic characteristics and chronic diseases on mortality of COVID-19: Retrospective study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
01
2021
accepted:
25
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
23
9
2021
Statut:
epublish
Résumé
Epidemiological features characterization of COVID-19 is highly important for developing and implementing effective control measures. In Saudi Arabia mortality rate varies between 0.6% to 1.26%. The purpose of the study was to investigate whether demographic characteristics (age and gender) and non-communicable diseases (Hypertension and Diabetes mellitus) have a significant association with mortality in COVID-19 patients. Prior to data collection, an expedite approval was obtained from Institutional Review Board (IRB Log No: RC. RC20.09.10) in Al Habib Research Center at Dr. Sulaiman Al-Habib Medical Group, Riyadh, Saudi Arabia. This is a retrospective design where we used descriptive and inferential analysis to analyse the data. Binary logistic regression was done to study the association between comorbidities and mortality of COVID-19. 43 (86%) of the male patients were non-survivors while 7 (14%) of the female patients were survivors. The odds of non-survivors among hypertensive patients are 3.56 times higher than those who are not having a history of Hypertension (HTN). The odds of non-survivors among diabetic patients are 5.17 times higher than those who are not having a history of Diabetes mellitus (DM). The odds of non-survivors are 2.77 times higher among those who have a history of HTN and DM as compared to those who did not have a history of HTN and DM. Those patients that had a history of Hypertension and Diabetes had a higher probability of non-survival in contrast to those who did not have a history of Diabetes and hypertension. Further studies are required to study the association of comorbidities with COVID-19 and mortality.
Sections du résumé
BACKGROUND
Epidemiological features characterization of COVID-19 is highly important for developing and implementing effective control measures. In Saudi Arabia mortality rate varies between 0.6% to 1.26%. The purpose of the study was to investigate whether demographic characteristics (age and gender) and non-communicable diseases (Hypertension and Diabetes mellitus) have a significant association with mortality in COVID-19 patients.
METHODS
Prior to data collection, an expedite approval was obtained from Institutional Review Board (IRB Log No: RC. RC20.09.10) in Al Habib Research Center at Dr. Sulaiman Al-Habib Medical Group, Riyadh, Saudi Arabia. This is a retrospective design where we used descriptive and inferential analysis to analyse the data. Binary logistic regression was done to study the association between comorbidities and mortality of COVID-19.
RESULTS
43 (86%) of the male patients were non-survivors while 7 (14%) of the female patients were survivors. The odds of non-survivors among hypertensive patients are 3.56 times higher than those who are not having a history of Hypertension (HTN). The odds of non-survivors among diabetic patients are 5.17 times higher than those who are not having a history of Diabetes mellitus (DM). The odds of non-survivors are 2.77 times higher among those who have a history of HTN and DM as compared to those who did not have a history of HTN and DM.
CONCLUSIONS
Those patients that had a history of Hypertension and Diabetes had a higher probability of non-survival in contrast to those who did not have a history of Diabetes and hypertension. Further studies are required to study the association of comorbidities with COVID-19 and mortality.
Identifiants
pubmed: 34506551
doi: 10.1371/journal.pone.0257131
pii: PONE-D-21-01309
pmc: PMC8432755
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0257131Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Diabetes Res Clin Pract. 2021 Feb;172:108538
pubmed: 33189790
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Open Forum Infect Dis. 2020 Apr 29;7(5):ofaa153
pubmed: 32455147
J Infect. 2020 Sep;81(3):e44-e47
pubmed: 32593655
J Infect Public Health. 2020 Jul;13(7):920-925
pubmed: 32534945
J Med Virol. 2020 Jun;92(6):612-617
pubmed: 32108351
Eur J Med Res. 2021 May 24;26(1):47
pubmed: 34030733
Diabetes Metab Res Rev. 2020 Mar 31;:e3319
pubmed: 32233013
Int J Gen Med. 2021 Jul 21;14:3719-3728
pubmed: 34321917
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Infect Public Health. 2020 Nov;13(11):1639-1644
pubmed: 33004305
Trop Med Infect Dis. 2020 Nov 28;5(4):
pubmed: 33260553
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151
pubmed: 32064853
JAMA. 2020 Apr 21;323(15):1488-1494
pubmed: 32125362
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
J Renin Angiotensin Aldosterone Syst. 2020 Apr-Jun;21(2):1470320320926899
pubmed: 32408793
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet Diabetes Endocrinol. 2020 Oct;8(10):813-822
pubmed: 32798472
J Med Virol. 2020 Jun;92(6):577-583
pubmed: 32162702
Eur J Med Res. 2020 Nov 25;25(1):61
pubmed: 33239068
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528